NICE National Institute for Health and Care Excellence

Single Technology Appraisal

Talimogene laherparepvec for treating metastatic melanoma [ID508]

Committee Papers

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

SINGLE TECHNOLOGY APPRAISAL

Talimogene laherparepvec for treating metastatic melanoma [ID508]

Contents:

1. **Pre-Meeting Briefing**

2. **Final Scope and Final Matrix of Consultees and Commentators**

3. Company submission from **Amgen**

4. Company PAS submission from **Amgen**

5. **Clarification letters**
   - NICE request to the company for clarification on their submission
   - Company response to NICE's request for clarification

6. **Patient group, professional group and NHS organisation submission** from:
   - British Association of Skin Cancer Specialist Nurses (BASCSN)

7. **Expert statements** from:
   - Professor Christian Ottensmeier, Professor of Experimental Cancer medicine, and Consultant Medical Oncologist– clinical expert, nominated by NCRI/RCP/RCR/ACP
   - Professor Kevin Harrington, Professor of biological cancer therapies– clinical expert, nominated by Amgen and Melanoma UK
   - Mrs Jackie Hodgetts, Nurse clinician –clinical expert, nominated by British Association of Skin Cancer Specialist Nurses
   - Mrs Gillian Nuttall, Patient expert nominated by Melanoma Focus

8. **Evidence Review Group report** prepared by **Liverpool Reviews & Implementation Group (LRiG)**

9. **Evidence Review Group report – factual accuracy check**

10. **Evidence Review Group report Group – Erratum**

Any information supplied to NICE which has been marked as confidential, has been redacted. All personal information has also been redacted.